HRAS
HRAS (HRas proto-oncogene, GTPase, also known as HRAS1) is a small GTPase of the Ras family that acts as a signal transducer in the Ras-MAPK pathway, regulating cell proliferation and survival. It binds GDP and GTP and has intrinsic GTPase activity. Browse Assay Genie's current range of HRAS research reagents below, or read on for the biology behind the target.
HRAS is a signal transducer in the Ras-MAPK signalling pathway, which regulates cell proliferation and survival. Like other Ras proteins, it binds GDP and GTP and possesses intrinsic GTPase activity, so it works as a nucleotide-dependent molecular switch. The protein is recognised by LZTR1, which mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.
The HRAS gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The HRAS protein belongs to the small GTPase superfamily and the RAS type GTPase family. It is found at the cell membrane, the Golgi apparatus and its membrane, the nucleus, and the cytoplasm, including the perinuclear region. HRAS undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Multiple transcript variants encoding different isoforms have been identified. Mouse and rat both have an orthologous Hras gene.
The name reflects the gene's origin: it was previously listed as v-Ha-ras Harvey rat sarcoma viral oncogene homolog, with the earlier symbol HRAS1. Mutations in the HRAS gene cause Costello syndrome, a disorder characterised by increased prenatal growth, postnatal growth deficiency, predisposition to tumour formation, cognitive disability, skin and musculoskeletal abnormalities, a distinctive facial appearance and cardiovascular abnormalities. Defects in the gene are also implicated in several cancers, including bladder cancer, follicular thyroid cancer and oral squamous cell carcinoma. This makes HRAS a frequent subject for studies of oncogenic signalling and RASopathies.
HRAS transduces signals through the Ras-MAPK pathway that regulate cell proliferation and survival, making it central to growth-signalling research.
Defects in HRAS are implicated in bladder cancer, follicular thyroid cancer and oral squamous cell carcinoma.
Mutations in the HRAS gene cause Costello syndrome, a developmental disorder with tumour predisposition and cardiovascular abnormalities.
HRAS cycles through palmitoylation and de-palmitoylation, which governs its exchange between the plasma membrane and the Golgi apparatus.
HRAS is a signal transducer in the Ras-MAPK pathway, which regulates cell proliferation and survival. It binds GDP and GTP and has intrinsic GTPase activity. Its levels are also controlled by LZTR1, which mediates its ubiquitination by a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex.
HRAS is also called GTPase HRas, and the earlier symbol was HRAS1. Previous gene names were v-Ha-ras Harvey rat sarcoma viral oncogene homolog and Harvey rat sarcoma viral oncogene homolog. Multiple transcript variants encode different isoforms.
Mutations in HRAS cause Costello syndrome, and defects are implicated in bladder cancer, follicular thyroid cancer and oral squamous cell carcinoma. Mouse and rat each have an orthologous Hras gene; check the datasheet of any product for its validated reactivity.
Other Ras family GTPases, Ras-MAPK pathway components and regulators of HRAS ubiquitination with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P01112; product specifications from Assay Genie datasheets.